Young adults diagnosed with high grade gliomas: Patterns of care, outcomes, and impact on employment.

Autor: Hafeez U; Department of Medical Oncology, Austin Hospital, Melbourne, Australia; La Trobe University School of Cancer Medicine, Melbourne, Australia; Olivia Newton-John Cancer Wellness and Research Centre, Melbourne, Australia., Menon S; Monash Health, Melbourne, Australia., Nguyen B; Sir Charles Gairdner Hospital, Perth, Australia., Lum C; Monash Health, Melbourne, Australia., Gaughran G; Canberra Hospital, Canberra, Australia., Pranavan G; Canberra Hospital, Canberra, Australia., Cher L; Department of Medical Oncology, Austin Hospital, Melbourne, Australia., Nowak AK; Sir Charles Gairdner Hospital, Perth, Australia; Medical School, University of Western, Australia., Gan HK; Department of Medical Oncology, Austin Hospital, Melbourne, Australia; La Trobe University School of Cancer Medicine, Melbourne, Australia; Olivia Newton-John Cancer Wellness and Research Centre, Melbourne, Australia; Department of Medicine, University of Melbourne, Melbourne, Australia., Parakh S; La Trobe University School of Cancer Medicine, Melbourne, Australia; Olivia Newton-John Cancer Wellness and Research Centre, Melbourne, Australia; Monash Health, Melbourne, Australia. Electronic address: sagun.parakh@monashhealth.org.
Jazyk: angličtina
Zdroj: Journal of clinical neuroscience : official journal of the Neurosurgical Society of Australasia [J Clin Neurosci] 2019 Oct; Vol. 68, pp. 45-50. Date of Electronic Publication: 2019 Jul 29.
DOI: 10.1016/j.jocn.2019.07.063
Abstrakt: There is limited information on the patterns of care and outcomes of high grade gliomas (HGGs) in young adults, in particular, the impact it has on a person's employment. We retrospectively identified young adult patients (age ≤ 40 years old) with newly diagnosed high grade gliomas treated between January 2013 and June 2018 across four major neuro-oncology centres in Australia. Patient demographics, tumour characteristics and treatment parameters were collected and outcomes determined. A total of 113 patients were identified with a median follow up of 27.0 months (range 1.0-70.2 months). The median age was 31 years, majority were male (65%) and employed (71.6%). IDH mutations were detected in 66 (62%) cases. The median progression-free survival (PFS) was 38.0 months (95% CI 23.3-52.7 months) and median overall survival (OS) was not reached. Patients with IDH wild type anaplastic astrocytoma and glioblastoma had a significantly shorter median PFS (19.3 months vs. NR, p = 0.001) and median OS (43.5 months vs NR, p = 0.007) than those with IDH mutated grade III anaplastic astrocytoma and oligodendroglioma. There was no significant difference in median OS or PFS between patients who underwent gross or subtotal tumour resection. Significantly, after diagnosis only 36 (32%) patients reported being employed. Young patients with IDH wild type astrocytomas and glioblastoma had better outcomes than reported historical controls. Most patients did not continue in employment post diagnosis.
(Copyright © 2019 Elsevier Ltd. All rights reserved.)
Databáze: MEDLINE
Externí odkaz: